28bio

About 28bio

AxoSim operates in the biotechnology sector, focusing on revolutionizing the drug development process. The company provides predictive human data through its high-quality 3D miniature brain organoids, which serve as human-relevant models in preclinical drug discovery. This technology aims to address the inefficiencies in traditional drug development, where nearly 90% of drugs that appear promising in animal models fail in human trials. AxoSim's solutions offer clinically relevant functional and structural metrics, significantly improving the success rates of R&D efforts. By delivering accurate preclinical testing, AxoSim helps researchers predict human outcomes in the lab, making the development of safer and more effective drugs possible. The company primarily serves pharmaceutical and biotechnology firms looking to streamline their research processes, save time, and reduce costs. AxoSim's business model revolves around providing these advanced testing services, generating revenue through service contracts with its clients.